Buckley Peter F
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912-3800, USA.
Drugs Today (Barc). 2003 Feb;39(2):145-51. doi: 10.1358/dot.2003.39.2.799421.
Aripiprazole, the latest atypical antipsychotic to come to clinical practice, has a proposed mechanism of action different to other agents, most notably in its partial agonist action at dopamine (D2) receptors and at serotonin (5HT1A) receptors. Placebo-controlled comparative trials of aripiprazole confirm efficacy for positive, negative and general psychopathology. Treatment-emergent adverse effects appear low. Aripiprazole is associated with low propensity for extrapyramidal side effects, an absence hyperprolactinemia and a low propensity for weight gain. Aripiprazole's clinical role will be determined by clinical experience, additional phase IV studies, and comparative information for this agent with respect to the efficacy and tolerability profiles of other atypical antipsychotic medications.
阿立哌唑是最新用于临床实践的非典型抗精神病药物，其作用机制与其他药物不同，最显著的是它对多巴胺（D2）受体和5-羟色胺（5HT1A）受体具有部分激动剂作用。阿立哌唑的安慰剂对照比较试验证实了其对阳性、阴性及一般精神病理学症状均有效。治疗中出现的不良反应似乎较少。阿立哌唑导致锥体外系副作用的倾向较低，不会引起高泌乳素血症，体重增加的倾向也较低。阿立哌唑的临床作用将由临床经验、更多的IV期研究以及该药物与其他非典型抗精神病药物在疗效和耐受性方面的比较信息来决定。
